Peregrine Pharmaceuticals

Dr. Robert Garnick has joined Peregrine Pharmaceuticals as the head of regulatory affairs. Dr. Garnick was formerly the senior vice president of regulatory, quality and compliance at Genentech. During his 24-year career at that company, he was responsible for 17 new product approvals, including most of the company’s top selling monoclonal antibody therapeutics such as Rituxan, Herceptin, Avastin and Lucentis. Dr. Garnick will be responsible for overseeing Peregrine’s interactions with the FDA and regulatory agencies around the world, and will lead the development of the company’s regulatory strategies for advancing its novel MAb-based treatments for cancer and infectious diseases.

“Rob has an unparalleled track record in the biotechnology and pharmaceutical industry, having led the regulatory, quality and compliance strategy for developing many of the most successful monoclonal antibody therapeutics currently on the market representing multiple disease areas,” said Steven W. King, president and chief executive officer of Peregrine. “His profound understanding of every aspect of the regulatory process and how it impacts clinical design and drug development is already proving invaluable as we prepare for the next stage of clinical development for our innovative drug candidates bavituximab and Cotara. We have made considerable progress over the past few years in our clinical programs and bringing Rob’s expertise and experience on board at this critical time is a significant development for the company.”

Dr. Garnick has over 30 years of experience in drug and biologic pharmaceutical development. He joined Genentech in 1984 and after a series of promotions, he became vice president of quality in 1994 and was later promoted to senior vice president of regulatory, quality and compliance in 2001. In this role, Dr. Garnick was responsible for all the regulated aspects of Genentech’s business including drug development, commercial production and promotional and labeling compliance. After leaving Genentech in 2008, Dr. Garnick founded Lone Mountain Biotechnology and Medical Devices Inc., a successful company specializing in drug and device consulting where he remains as president and chief executive officer.